iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally.
Adequate balance sheet with limited growth.
Share Price & News
How has iCAD's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ICAD's share price has been volatile over the past 3 months.
7 Day Return
US Healthcare Services
1 Year Return
US Healthcare Services
Return vs Industry: ICAD exceeded the US Healthcare Services industry which returned 24.2% over the past year.
Return vs Market: ICAD exceeded the US Market which returned 20.1% over the past year.
Price Volatility Vs. Market
How volatile is iCAD's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StIf You Had Bought iCAD (NASDAQ:ICAD) Stock Three Years Ago, You Could Pocket A 137% Gain Today
1 month ago | Simply Wall StMarket Sentiment Around Loss-Making iCAD, Inc. (NASDAQ:ICAD)
2 months ago | Simply Wall StWhat Kind Of Shareholder Owns Most iCAD, Inc. (NASDAQ:ICAD) Stock?
Is iCAD undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ICAD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ICAD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ICAD is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.
PE vs Market: ICAD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ICAD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ICAD is overvalued based on its PB Ratio (28.2x) compared to the US Healthcare Services industry average (3.7x).
How is iCAD forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICAD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ICAD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ICAD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ICAD's revenue (26.3% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: ICAD's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ICAD's Return on Equity is forecast to be high in 3 years time
How has iCAD performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICAD is currently unprofitable.
Growing Profit Margin: ICAD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ICAD is unprofitable, but has reduced losses over the past 5 years at a rate of 5.6% per year.
Accelerating Growth: Unable to compare ICAD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ICAD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (12.1%).
Return on Equity
High ROE: ICAD has a negative Return on Equity (-165.37%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is iCAD's financial position?
Financial Position Analysis
Short Term Liabilities: ICAD's short term assets ($29.2M) exceed its short term liabilities ($16.6M).
Long Term Liabilities: ICAD's short term assets ($29.2M) exceed its long term liabilities ($16.8M).
Debt to Equity History and Analysis
Debt Level: ICAD's debt to equity ratio (221.2%) is considered high.
Reducing Debt: ICAD's debt to equity ratio has increased from 20.5% to 221.2% over the past 5 years.
Inventory Level: ICAD has a low level of unsold assets or inventory.
Debt Coverage by Assets: ICAD's debt is covered by short term assets (assets are 1.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ICAD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ICAD has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of -24.5% each year.
What is iCAD's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ICAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ICAD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICAD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICAD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ICAD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Klein (65yo)
Mr. Michael S. Klein, also known as Mike, has been Executive Chairman of iCAD, Inc. since November 9, 2018. Mr. Mike is Chief Executive Officer of iCAD, Inc. since December 12, 2018. Mr. Mike was an Interi ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD1.63M) is above average for companies of similar size in the US market ($USD1.11M).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
|Executive Chairman & CEO||1.3yrs||US$1.63m||no data|
|Chief Financial Officer||1.2yrs||US$284.63k||0.19% $442.2k|
|Chief Technology Officer||1.1yrs||US$501.46k||0.51% $1.2m|
|Vice President of Administration||0yrs||US$177.53k||no data|
Experienced Management: ICAD's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
|Executive Chairman & CEO||1.3yrs||US$1.63m||no data|
|Director||0.08yrs||no data||0.38% $871.3k|
|Independent Director||1.4yrs||US$12.64k||no data|
|Independent Director||4.2yrs||US$52.73k||6.55% $15.2m|
|Independent Director||1.4yrs||US$12.02k||0.25% $587.6k|
Experienced Board: ICAD's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.7%.
iCAD, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: iCAD, Inc.
- Ticker: ICAD
- Exchange: NasdaqCM
- Founded: 1984
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$232.097m
- Shares outstanding: 19.37m
- Website: https://www.icadmed.com
Number of Employees
- iCAD, Inc.
- 98 Spit Brook Road
- Suite 100
- New Hampshire
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ICAD||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Dec 1984|
|HWT1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 1984|
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Platform, a server residing on a customer’s network that receives patient studies from the imaging modality, performs analysis, and sends results to picture archiving and communication system and/or review workstations. In addition, the company offers magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 23:41|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.